Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
InBody CoXKRX:041830 -3.60%86 Net Margin % is 19.33% as of Jun. 2026, which is 4% below its 10-year median of 20.23. GuruFocus rates XKRX:041830 with a GF Score™ of 86/100 and a GF Value™ of ₩35,473.99 (Significantly Overvalued). The stock has 1 warning sign investors should review. Among 816 Medical Devices & Instruments companies, InBody Co ranks better than 86.03% on this metric.
Net margin is calculated as Net Income divided by its Revenue. InBody Co's Net Income for the
three
months ended in Jun. 2026 was ₩14,160 Mil. InBody Co's Revenue for the
three
months ended in Jun. 2026 was ₩73,254 Mil. Therefore, InBody Co's net margin for the quarter that ended in Jun. 2026 was 19.33%.
The historical rank and industry rank for InBody Co's Net Margin % or its related term are showing as below:
XKRX:041830'
s Net Margin % Range Over the Past 10 Years
Min: 13.09 Med: 20.23 Max: 24.69
Current: 17.64
XKRX:041830's Net Margin % is ranked better than 86.03% of 816
companies
in the Medical Devices & Instruments industry
Industry Median: 2.39
vs XKRX:041830: 17.64
Although Net Income and Earnings-per-Share (EPS) are the most widely used parameter in measuring a company's profitability and valuation, it is the least reliable. The reason is that reported earnings can be manipulated easily by adjusting any numbers such as Depreciation, Depletion and Amotorization and non-recurring items.
But the long term trend of the net margin is a good indicator of the competitiveness and health of the business.
InBody Co Net Margin % Related Terms
InBody Co Net Margin % Historical Data
* Premium members only.
The historical data trend for InBody Co's Net Margin % can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
XKRX:041830 vs ABT, SYK, MDT: Net Margin % Comparison
For the Medical Devices subindustry, InBody Co's Net Margin %, along with its competitors' market caps and Net Margin % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
InBody Co Net Margin % vs Medical Devices & Instruments Industry
For the Medical Devices & Instruments industry and Healthcare sector, InBody Co's Net Margin % distribution charts can be found below:
* The bar in red indicates where InBody Co's Net Margin % falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
InBody Co (XKRX:041830) has a Net Margin % of 19.33% as of Jun. 2026. Net margin is the ratio of total net income to net sales. View historical data on InBody Co and its competitors. This is near median its historical median of 20.23. Over the past decade, InBody Co's Net Margin % has ranged from 13.09 to 24.69. According to the industry distribution chart, InBody Co ranks #114 out of 816 companies in the Medical Devices & Instruments industry, placing it in the top 14%.
Is InBody Co's Net Margin % too high?
InBody Co's current Net Margin % of 19.33% is near median its 10-year median of 20.23. Over the past 10 years, this metric has ranged from a low of 13.09 to a high of 24.69. The Medical Devices & Instruments industry median Net Margin % is 2.39. InBody Co's value of 19.33% is 708.8% above this industry median. Based on the distribution chart, InBody Co ranks #114 out of 816 companies in the Medical Devices & Instruments industry, which is in the top quartile — a strong position relative to peers. Overall, InBody Co has a GF Score™ of 86/100 and is considered Significantly Overvalued, reflecting its overall financial health beyond just this single metric.
How does InBody Co's Net Margin % compare to ABT and SYK?
According to the Medical Devices & Instruments industry distribution chart, InBody Co ranks #114 out of 816 companies for Net Margin %. This places InBody Co in the top 14% of its industry — outperforming the majority of peers. The industry median Net Margin % is 2.39. InBody Co's value of 19.33% is 708.8% above this benchmark. Historically, InBody Co's own Net Margin % has ranged from 13.09 to 24.69 over the past decade. While the company's 10-year median is 20.23 vs. the industry median of 2.39, InBody Co has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Net Margin % for a Medical Devices & Instruments company?
The median Net Margin % among Medical Devices & Instruments companies is 2.39, based on 816 companies in the industry. Companies in the top quartile (top 25%) have a Net Margin % significantly above this median, while those in the bottom quartile fall well below. However, Net Margin % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. InBody Co's current Net Margin % of 19.33% is 708.8% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Net Margin % mean?
A high Net Margin % can signal that a stock is expensive relative to its fundamentals. Net margin is the ratio of total net income to net sales. View historical data on InBody Co and its competitors. For the Medical Devices & Instruments industry, the median Net Margin % is 2.39 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. InBody Co's current Net Margin % is 19.33%, which is near median its own 10-year median of 20.23. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is InBody Co stock overvalued right now?
Based on GuruFocus' analysis, InBody Co (XKRX:041830) is currently considered Significantly Overvalued. The stock's GF Value™ is ₩35,473.99, compared to a current price of ₩58,900.00 — trading 66% above its estimated fair value. The current Net Margin % is 19.33%, which is near median its 10-year median of 20.23 and 708.8% above the Medical Devices & Instruments industry median of 2.39. InBody Co's overall GF Score™ is 86/100 with 1 warning sign to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Net Margin % calculated?
Net Margin % is calculated from a company's financial statements. For InBody Co (XKRX:041830), the current Net Margin % is 19.33% as of Jun. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is InBody Co (XKRX:041830) Overvalued in 2026?
Based on GuruFocus' analysis, InBody Co stock appears to be overvalued.
The current stock price of ₩58,900.00 is trading 66% above its estimated GF Value™ of ₩35,473.99.
GuruFocus considers InBody Co to be Significantly Overvalued.
Key valuation signals for XKRX:041830:
Net Margin %: 19.33% (near median its 10-year median of 20.23)
GF Value™: ₩35,473.99 vs. price of ₩58,900.00 (66% above fair value)
Industry Position: 708.8% above the Medical Devices & Instruments median (#114 of 816)
No single metric tells the full story. See the XKRX:041830 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
InBody Co Ltd is a Korea-based company engaged in the manufacturing and distribution of body composition analyzers. The company mainly produces body composition analyzers under the brand name InBody and Lookin'Body. It's InBody series products include InBody720, InBody570, InBody230, InBody J30, and InBody S10.
86GF Score
Get the complete analysis for XKRX:041830
Net Margin % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
XKRX:041830 has been successfully added to your 
